Ciara Kelly, MBBCh, BAO Recent developments in the gastrointestinal stromal tumor (GIST) treatment paradigm have substantially broadened treatment options for patients at all stages of this disease; however, further research is necessary to continue to make progress in this area, according to Ciara Kelly, MBBCh, BAO. “With the advancement in technology with respect to molecularly characterizing tumors, including GIST, what I’m hopeful that we will see is greater optimization of treatment decision-making,” Kelly said in an interview with OncLive ® ahead of GIST Awareness Day, which takes place every year on July 13. In the interview, Kelly, the interim clinical director of the Sarcoma Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York, discussed standard-of-care (SOC) GIST treatment options for patients across all lines of therapy, ongoing trials to keep to watch in the GIST space, and the importance of providing comprehensive supportive care to patients with GIST.
Kelly highlighted data from the phase 3 INTRIGUE trial (NCT03673501), in which patients with GIST harboring only mutations in KIT exon 11 and exons 13/14 achieved a median progression-free survival (PFS) of 15.0 months with sunitinib (Sutent; n = 21) vs 4.0 months with ripretinib (Qinlock; n = 20; HR, 3.
94; 95% CI, 1.71-9.11; nominal P = .
0005;). 1 PFS outcomes with ripretinib were more favorable than those with sunitinib in patients with mutations in KIT exon 11 and exons .